Anti-TCR-alphabeta monoclonal antibody R73

Drug Profile

Anti-TCR-alphabeta monoclonal antibody R73

Alternative Names: Alpha-beta-TCR monoclonal antibody R73; Anti-T-cell-receptor-alphabeta antibody R73; Anti-T-cell-receptor-alphabeta monoclonal antibody R73; Anti-TCR-alphabeta antibody R73; Monoclonal antibody R73; R73

Latest Information Update: 03 Jul 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Aventis Behring LLC; Nonindustrial source
  • Class Monoclonal antibodies
  • Mechanism of Action T-cell receptor antigen alpha-beta antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Transplant rejection

Most Recent Events

  • 24 Dec 1999 Hoechst has merged with Rhône-Poulenc to form Aventis
  • 09 Jul 1998 A preclincial study has been added to the pharmacodynamics section
  • 04 Sep 1996 A study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top